Next Article in Journal
A Rare Case of Fatal Endobronchial Mucormycosis Masquerading as Endobronchial Tuberculosis
Previous Article in Journal
Rare Breast Carcinoma with Paradoxical Plasma Cell Immunoprofile: A Case Report
Open AccessArticle

A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment

1
Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan
2
Department of Pharmacy, Chi Mei Medical Center, Liouying 73657, Tainan, Taiwan
3
Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch 71051, Tainan, Taiwan
4
Department of Pharmacy, Chi Mei Medical Center, Liouying 73657, Tainan, Taiwan
5
Department of Pediatrics, Chi Mei Medical Center, Liouying 73657, Tainan, Taiwan
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Medicina 2020, 56(2), 63; https://doi.org/10.3390/medicina56020063
Received: 24 December 2019 / Revised: 2 February 2020 / Accepted: 4 February 2020 / Published: 5 February 2020
Background and Objectives: This meta-analysis compared the efficacy and safety of peramivir compared to other neuraminidase inhibitors (NAIs). Materials and Methods: Data from PubMed, Embase, and Cochrane databases and ClinicalTrials.gov were searched until January 2019. Randomized controlled trials (RCTs) and observational studies (OSs) comparing peramivir with other NAIs for treating influenza were included. The Grading of Recommendations, Assessments, Development, and Evaluations (GRADE) system was used to judge the overall certainty of evidence; the result was moderate. The primary outcome was time to alleviation of symptoms. Twelve articles involving 2681 patients were included in this meta-analysis. We used a random-effect model to pool the effect size, which is expressed as the difference in means (MD), risk ratio (RR), and 95% confidence interval (CI). Results: Overall, peramivir was superior to other NAIs (MD = −11.214 hours, 95% CI: −19.119 to −3.310). The incidence of adverse events (RR = 1.023, 95% CI: 0.717 to 1.460) and serious adverse events (RR = 1.068, 95% CI: 0.702 to 1.625) in the peramivir group was similar to those in the oseltamivir group. In addition, peramivir had higher efficacy than each NAI alone. Conclusion: In conclusion, the efficacy of peramivir might be higher than that of other NAIs, and this agent is tolerated as well as other NAIs.
Keywords: peramivir; neuraminidase inhibitors; influenza peramivir; neuraminidase inhibitors; influenza
MDPI and ACS Style

Chen, J.-Y.; Wei, S.-K.; Lai, C.-C.; Weng, T.-S.; Wang, H.-H. A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment. Medicina 2020, 56, 63.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop